{"product_id":"myriad-pestle-analysis","title":"Myriad PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our Myriad PESTLE Analysis—three to five pages of distilled insight into political, economic, social, technological, legal, and environmental forces shaping Myriad's future. Perfect for investors, consultants, and planners who need actionable intelligence fast. Buy the full version now for the complete, editable report and start making smarter decisions today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth policy \u0026amp; reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare and Medicaid coverage decisions directly shape test adoption and pricing, as the programs together cover over 120 million Americans. Shifts to value-based care and preventative priorities are elevating genetics in oncology, women’s health and pharmacogenomics. Policy volatility around diagnostic reimbursement forces rapid coding and strategy updates. Active engagement and advocacy with CMS can mitigate adverse rate cuts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulation of LDTs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2025 the FDA’s phased LDT oversight increases compliance costs and lengthens timelines for Myriad, raising regulatory burden across assay validation and reporting. Political support or congressional pushback will shape enforcement discretion and any grandfathering provisions that affect existing menus. Close alignment with CLIA and FDA expectations is critical to maintain menu stability. Transition plans could slow launch cadence and constrain market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal research funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNIH, the largest public biomedical funder with an annual budget around $50 billion, and the Biden-era Cancer Moonshot drive expanded genomics evidence generation and clinical utility through targeted grants and initiatives.\u003c\/p\u003e\n\u003cp\u003eGrant cycles and appropriations are politically sensitive, with funding levels often shifting after elections and appropriations battles in Congress.\u003c\/p\u003e\n\u003cp\u003ePublic-private partnerships and targeted funding boosts have accelerated trials and real-world evidence programs, opening collaborative validation opportunities for diagnostic firms like Myriad.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics \u0026amp; supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTariffs (Section 301 duties up to 25%) and tightened export controls on advanced semiconductors since 2022 raise costs and constrain supply of reagents, sequencers and chips; political scrutiny of China-linked sourcing is driving supplier diversification and reshoring. Customs delays lengthen kit availability and turnaround times, while CHIPS Act funding of roughly 52 billion USD for domestic fabs lowers dependency risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs: Section 301 up to 25%\u003c\/li\u003e\n\u003cli\u003eExport controls: tightened since 2022 on advanced chips\u003c\/li\u003e\n\u003cli\u003eSupply risk: China-sourcing scrutiny → diversification\u003c\/li\u003e\n\u003cli\u003eIncentives: CHIPS Act ~52B USD for domestic manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-level initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUS states diverge on genetic privacy, telehealth coverage, and lab licensing, creating fragmented compliance for Myriad; over 30 states now participate in telehealth licensure compacts or parity rules as of 2024. All 50 states mandate newborn screening but panels vary (28–61 conditions), and Medicaid covers roughly 20% of the population, driving uneven regional demand. State tax credits, grants, and site-selection incentives have shifted lab siting and employment patterns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003etelehealth compacts: \u0026gt;30 states (2024)\u003c\/li\u003e\n\u003cli\u003enewborn panels: 28–61 conditions\u003c\/li\u003e\n\u003cli\u003emedicaid: ~20% population\u003c\/li\u003e\n\u003cli\u003estate incentives: influence lab siting\/employment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare\/Medicaid, FDA LDT rules, funding and trade reshape diagnostics access and costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare\/Medicaid influence pricing and access for \u0026gt;120M beneficiaries; Medicaid covers ~20% of population. FDA phased LDT oversight (2025) raises validation\/compliance costs and may slow launches. NIH budget ~$50B and Cancer Moonshot expand genomics evidence funding; CHIPS Act ~$52B and Section 301 tariffs up to 25% affect supply chains. State divergence (\u0026gt;30 telehealth compacts) fragments market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical Factor\u003c\/th\u003e\n\u003cth\u003eKey Data (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;120M covered; Medicaid ~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA LDT oversight\u003c\/td\u003e\n\u003ctd\u003ephased 2025—higher compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH\/Cancer funding\u003c\/td\u003e\n\u003ctd\u003eNIH ~$50B; Moonshot support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade \u0026amp; supply\u003c\/td\u003e\n\u003ctd\u003eSection 301 up to 25%; CHIPS ~$52B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState policy\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30 telehealth compacts; newborn panels 28–61\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Myriad across Political, Economic, Social, Technological, Environmental, and Legal dimensions, providing data-backed trends, forward-looking insights and actionable subpoints tailored for executives, investors and strategists—ready for plans, decks, or reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Myriad PESTLE summary for quick reference in meetings, easily editable to add regional or business-line notes and exportable into slides or Excel for rapid team alignment and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer mix \u0026amp; pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial payers, Medicare and Medicaid negotiate aggressively on diagnostics, with PAMA (Protecting Access to Medicare Act, implemented 2018) establishing median-based rate setting that has compressed margins across the diagnostic sector.\u003c\/p\u003e\n\u003cp\u003ePrior authorization requirements have increased administrative friction and denials, with industry reports noting materially higher denial rates for genetic testing in recent years.\u003c\/p\u003e\n\u003cp\u003ePrice discipline must balance patient access and utilization management against sustaining profitability amid ongoing reimbursement pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacro cycles \u0026amp; funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising inflation (US CPI ~3.4% in 2024) and central bank policy (fed funds ~5.25–5.50% in 2024–25) lift operating costs and patient out‑of‑pocket burdens, compressing margins. Tighter capital markets and a roughly 30% pullback in healthtech\/biotech VC versus peak years constrain R\u0026amp;D budgets and M\u0026amp;A optionality. Hospital\/practice budget pressure reduces routine test utilization while economic slowdowns tend to defer elective testing and boost demand for cost‑effective risk stratification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemographics \u0026amp; demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAging populations raise cancer incidence and genetic-testing eligibility—US new cancer cases estimated 1.96M in 2024 (ACS) and global cases rising toward 30M by 2040 (IARC). Rising mental-health diagnoses—WHO estimates 280M with depression—drive pharmacogenomic adoption. Women’s screenings and fertility shifts expand addressable markets; global ART market ~30B in 2024. Preventive-care economics favor earlier genetic risk assessment to lower downstream costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition \u0026amp; consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRapid innovation and new entrants intensify price and feature competition, pressuring margins; the companion diagnostics market was about $3.1B in 2024, creating premium niches where Myriad can partner with pharma. Payer-preferred lab networks and Medicare Advantage growth (over 50% enrollment in 2024) can exclude smaller vendors, while health system consolidation (≈60% of hospitals in systems by 2024) centralizes purchasing power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInnovation: higher R\u0026amp;D pressure\u003c\/li\u003e\n\u003cli\u003ePayer networks: access risk to smaller labs\u003c\/li\u003e\n\u003cli\u003eConsolidation: centralized purchasing\u003c\/li\u003e\n\u003cli\u003eCDx partnerships: premium revenue niches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAutomation, higher-throughput sequencing and lean logistics materially lower COGS for Myriad; sequencing costs have fallen over 99% since 2007, with whole-genome costs below $1,000 by 2021, enabling cheaper per-test economics. Faster turnaround times increase physician loyalty and test volume, while scale in data analytics improves gross margins. Efficient revenue-cycle management cuts denials and shortens DSO.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutomation: lower COGS\u003c\/li\u003e\n\u003cli\u003eThroughput: cheaper per-test\u003c\/li\u003e\n\u003cli\u003eTurnaround: higher physician volume\u003c\/li\u003e\n\u003cli\u003eData scale: margin uplift\u003c\/li\u003e\n\u003cli\u003eRCM: fewer denials, reduced DSO\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare\/Medicaid, FDA LDT rules, funding and trade reshape diagnostics access and costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReimbursement compression (PAMA) and prior‑auths tighten margins while price discipline must preserve access; US CPI ~3.4% (2024) and fed funds 5.25–5.50% (2024–25) raise costs and patient burden. Medicare Advantage \u0026gt;50% enrollment (2024) and health system consolidation centralize purchasing. Cancer incidence ~1.96M US cases (2024) expands demand; sequencing costs down \u0026gt;99% since 2007 (WGS \u0026lt; $1,000 by 2021).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI (US, 2024)\u003c\/td\u003e\n\u003ctd\u003e3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS cancer cases (2024)\u003c\/td\u003e\n\u003ctd\u003e1.96M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA enrollment (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencing cost drop\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99% since 2007\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMyriad PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Myriad PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. This screenshot reflects the real, final file with complete content and structure. No placeholders or teasers—download the identical document immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162424914297,"sku":"myriad-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/myriad-pestle-analysis.png?v=1762700559","url":"https:\/\/portersfiveforce.com\/products\/myriad-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}